Published in J Virol on February 01, 1989
Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol (1994) 22.96
Pathogenesis of human immunodeficiency virus infection. Microbiol Rev (1993) 5.88
Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. PLoS One (2013) 1.94
Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: implications for vaccine development. J Virol (1997) 1.90
Fc receptor-mediated antiviral antibodies. Curr Opin HIV AIDS (2009) 1.56
Evidence for a correlation between antibody-dependent cellular cytotoxicity-mediating anti-HIV-1 antibodies and prognostic predictors of HIV infection. J Clin Immunol (2001) 1.56
Cellular and humoral antigenic epitopes in HIV and SIV. Immunology (1992) 1.38
Recognition of a highly conserved region of human immunodeficiency virus type 1 gp120 by an HLA-Cw4-restricted cytotoxic T-lymphocyte clone. J Virol (1993) 1.35
Antibody-dependent cell-mediated cytotoxicity in simian immunodeficiency virus-infected rhesus monkeys. J Virol (2011) 1.32
Limited sequence evolution within persistently targeted CD8 epitopes in chronic human immunodeficiency virus type 1 infection. J Virol (2005) 1.29
Changes in the viral mRNA expression pattern correlate with a rapid rate of CD4+ T-cell number decline in human immunodeficiency virus type 1-infected individuals. J Virol (1995) 1.28
Antibody-dependent cellular cytotoxicity against primary HIV-infected CD4+ T cells is directly associated with the magnitude of surface IgG binding. J Virol (2012) 1.27
Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination. Curr Opin HIV AIDS (2007) 1.24
Major histocompatibility complex-restricted CD8+ cytotoxic T lymphocytes from horses with equine infectious anemia virus recognize Env and Gag/PR proteins. J Virol (1994) 1.24
Enhancement of human immunodeficiency virus type 1 infection by antisera to peptides from the envelope glycoproteins gp120/gp41. J Exp Med (1991) 1.23
Independent evolution of Fc- and Fab-mediated HIV-1-specific antiviral antibody activity following acute infection. Eur J Immunol (2014) 0.96
The role of infant immune responses and genetic factors in preventing HIV-1 acquisition and disease progression. Clin Exp Immunol (2003) 0.95
Characterization of the antigenic domains of the major core protein (p26) of equine infectious anemia virus. J Virol (1991) 0.93
Contact of human immunodeficiency virus type 1-infected and uninfected CD4+ T lymphocytes is highly cytolytic for both cells. J Virol (1995) 0.90
Expression of Mycobacterium tuberculosis and Mycobacterium leprae proteins by vaccinia virus. Infect Immun (1990) 0.89
Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160. J Clin Invest (1993) 0.87
Failure of ADCC to predict HIV-associated disease progression or outcome in a haemophiliac cohort. Clin Exp Immunol (1990) 0.87
B cell responses to HIV and the development of human monoclonal antibodies. Clin Exp Immunol (1992) 0.82
Deficient antibody-dependent cellular cytotoxicity against human immunodeficiency virus (HIV)-expressing target cells in perinatal HIV infection. Clin Diagn Lab Immunol (1999) 0.81
Autologous neutralizing antibody to human immunodeficiency virus-1 and replication-competent virus recovered from CD4+ T-cell reservoirs in pediatric HIV-1-infected patients on HAART. AIDS Res Hum Retroviruses (2010) 0.78
Development of IgG Mediated Antibody Dependent Cell-mediated Cytotoxicity (ADCC) in the Serum and Genital Mucosa of HIV Seroconverters. J AIDS Clin Res (2015) 0.75
Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature (1985) 30.62
The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature (1985) 30.47
General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. J Virol (1984) 10.98
HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature (1987) 7.88
Standardized and simplified nomenclature for proteins common to all retroviruses. J Virol (1988) 6.31
Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters. Proc Natl Acad Sci U S A (1983) 4.69
Distinctive nucleotide sequences adjacent to multiple initiation and termination sites of an early vaccinia virus gene. Cell (1981) 4.42
The isolation of simian virus 40 variants with specifically altered genomes. Proc Natl Acad Sci U S A (1974) 4.35
Nucleotide sequence of the vaccinia virus thymidine kinase gene and the nature of spontaneous frameshift mutations. J Virol (1983) 3.95
Expression of the HTLV-III envelope gene by a recombinant vaccinia virus. Nature (1986) 3.19
Molecular genetics of vaccinia virus: demonstration of marker rescue. Proc Natl Acad Sci U S A (1982) 3.01
Mapping of a gene coding for a major late structural polypeptide on the vaccinia virus genome. J Virol (1984) 2.44
Recognition of influenza A virus nucleoprotein by human cytotoxic T lymphocytes. J Gen Virol (1986) 2.16
Neutralization of HTLV-III/LAV replication by antiserum to thymosin alpha 1. Science (1986) 1.75
Sera from HTLV-III/LAV antibody-positive individuals mediate antibody-dependent cellular cytotoxicity against HTLV-III/LAV-infected T cells. J Immunol (1987) 1.74
Vaccinia virus vectors utilizing the beta-galactosidase assay for rapid selection of recombinant viruses and measurement of gene expression. Gene (1986) 1.64
Antibody-dependent cellular cytotoxicity-inducing antibodies against human immunodeficiency virus. Presence at different clinical stages. J Immunol (1987) 1.61
Exposure to human T-lymphotropic virus type III/lymphadenopathy-associated virus and immunologic abnormalities in asymptomatic homosexual men. Ann Intern Med (1985) 1.53
Antibodies to human immunodeficiency virus in human sera induce cell-mediated lysis of human immunodeficiency virus-infected cells. J Immunol (1987) 1.34
A monoclonal antibody against LAV gag precursor: use for viral protein analysis and antigenic expression in infected cells. J Immunol (1986) 1.25
Hemophiliac immunodeficiency: influence of exposure to factor VIII concentrate, LAV/HTLV-III, and herpesviruses. J Pediatr (1986) 1.11
Virulence factors of Escherichia coli in urinary isolates from pregnant women. J Infect Dis (1987) 1.10
Human monoclonal antibody directed against gag gene products of the human immunodeficiency virus. J Immunol (1988) 1.05
Antibody-dependent cellular cytotoxicity specific for the envelope antigens of human immunodeficiency virus. J Infect Dis (1988) 0.99
Antibody-dependent cellular cytotoxicity against Epstein-Barr virus-associated antigens in African patients with nasopharyngeal carcinoma. Int J Cancer (1978) 0.97
Epstein-Barr virus-specific antibody-dependent cellular cytotoxicity in patients with Burkitt's lymphoma. Int J Cancer (1979) 0.90
Potential human immunodeficiency virus-host cells in human semen. AIDS Res Hum Retroviruses (1988) 0.89
Immunologic cytotoxicity against autologous human lymphocytes transformed or infected by Epstein-Bar virus: role of antibody-dependent cellular cytotoxicity in health individuals. J Natl Cancer Inst (1980) 0.82
In vitro antibody-dependent cellular cytotoxicity against human T-cell leukemia/lymphoma virus (HTLV)-producing cells. Int J Cancer (1984) 0.81
Changes in thymic function with age and during the treatment of HIV infection. Nature (1998) 10.27
Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N Engl J Med (1995) 8.15
Severe herpesvirus infections in an adolescent without natural killer cells. N Engl J Med (1989) 7.52
Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc Natl Acad Sci U S A (1982) 7.04
Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med (1996) 4.44
Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat Med (2000) 4.12
Construction of live vaccines using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D. Proc Natl Acad Sci U S A (1984) 3.58
Characterization of human bone marrow fibroblast colony-forming cells (CFU-F) and their progeny. Blood (1980) 3.51
Iron and the sex difference in heart disease risk. Lancet (1981) 3.45
Definition, assessment and treatment of wheezing disorders in preschool children: an evidence-based approach. Eur Respir J (2008) 3.36
Molecular genetics of vaccinia virus: demonstration of marker rescue. Proc Natl Acad Sci U S A (1982) 3.01
Inflammatory breast cancer: the experience of the surveillance, epidemiology, and end results (SEER) program. J Natl Cancer Inst (1985) 2.95
International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol (2010) 2.94
Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin. Proc Natl Acad Sci U S A (1983) 2.79
Two major DNA variants present in serially propagated stocks of the WR strain of vaccinia virus. J Virol (1981) 2.74
High frequency of defective nef alleles in a long-term survivor with nonprogressive human immunodeficiency virus type 1 infection. J Virol (1996) 2.61
Arrangement of late RNAs transcribed from a 7.1-kilobase EcoRI vaccinia virus DNA fragment. J Virol (1984) 2.48
Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J Immunol (1995) 2.45
Effect of acid and pepsin on blood coagulation and platelet aggregation. A possible contributor prolonged gastroduodenal mucosal hemorrhage. Gastroenterology (1978) 2.41
Detection of major histocompatibility complex class I-restricted, HIV-specific cytotoxic T lymphocytes in the blood of infected hemophiliacs. Blood (1989) 2.37
Proposed definitions for in utero versus intrapartum transmission of HIV-1. N Engl J Med (1992) 2.33
Immune response after splenectomy. Lancet (1978) 2.31
A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res (2000) 2.28
Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus. Cancer Res (1981) 2.25
Factor concentrates for treatment of hemophilia: which one to choose? Blood (1989) 2.16
Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis (1998) 2.08
Unusual polymorphisms in human immunodeficiency virus type 1 associated with nonprogressive infection. J Virol (2000) 2.04
Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: control of viral replication and absence of persistent HIV-1-specific immune responses. J Virol (2000) 2.04
Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis (2007) 2.01
High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis (1995) 1.97
Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) (2002) 1.96
Cough and asthma in children. Pediatr Ann (1996) 1.95
Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology (1999) 1.92
Measles infection of human mononuclear cells. I. Acute infection of peripheral blood lymphocytes and monocytes. J Exp Med (1975) 1.86
Influenza virus infection in nude mice. J Infect Dis (1976) 1.85
An acute effect of cigarette smoking on platelet function. A possible link between smoking and arterial thrombosis. Circulation (1973) 1.84
Modulation of different human immunodeficiency virus type 1 Nef functions during progression to AIDS. J Virol (2001) 1.80
Serum theophylline levels in asthmatic children after oral administration of two slow-release theophylline preparations. Arch Dis Child (1978) 1.79
Characterization of the T cell-mediated cellular cytotoxicity during acute infectious mononucleosis. J Immunol (1989) 1.77
Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. Int J Radiat Oncol Biol Phys (1998) 1.72
Documentation of Epstein-Barr virus infection in immunodeficient patients with life-threatening lymphoproliferative diseases by Epstein-Barr virus complementary RNA/DNA and viral DNA/DNA hybridization. Cancer Res (1981) 1.72
Infrequent detection of HIV-1-specific, but not cytomegalovirus-specific, CD8(+) T cell responses in young HIV-1-infected infants. J Immunol (2001) 1.72
HIV-1-specific cytotoxic T lymphocyte responses in the first year of life. J Immunol (1995) 1.69
Declining CD4 T-cell counts in a person infected with nef-deleted HIV-1. N Engl J Med (1999) 1.69
Seroprevalence of human herpesvirus-8 (HHV-8) in countries of Southeast Asia compared to the USA, the Caribbean and Africa. Br J Cancer (1999) 1.68
Etiology of nasopharyngeal carcinoma: a review. Epidemiol Rev (1993) 1.66
Timing of events in normal swallowing: a videofluoroscopic study. Dysphagia (2000) 1.64
Vaccinia virus vectors utilizing the beta-galactosidase assay for rapid selection of recombinant viruses and measurement of gene expression. Gene (1986) 1.64
Prevalence of hepatitis C virus antibody in a cohort of hemophilia patients. Blood (1990) 1.64
Short-term corticosteroids then lamivudine and plasma exchanges to treat hepatitis B virus-related polyarteritis nodosa. Arthritis Rheum (2004) 1.63
Aetiology of AIDS--antibodies to human T-cell leukaemia virus (type III) in haemophiliacs. Nature (1984) 1.63
Pharmacokinetics of nevirapine: initial single-rising-dose study in humans. Antimicrob Agents Chemother (1993) 1.62
Organization of six early transcripts synthesized from a vaccinia virus EcoRI DNA fragment. J Virol (1984) 1.62
Sequence variations in human immunodeficiency virus type 1 Nef are associated with different stages of disease. J Virol (1999) 1.61
Epidemiology and clinical impact of hepatitis D virus (delta) infection. Hepatology (1985) 1.60
High levels of human peripheral blood mononuclear cell engraftment and enhanced susceptibility to human immunodeficiency virus type 1 infection in NOD/LtSz-scid/scid mice. J Infect Dis (1995) 1.58
Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team. N Engl J Med (1997) 1.56
Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.55
Lymphocyte cytotoxicity reactions to leukemia-associated antigens in identical twins. Int J Cancer (1972) 1.55
Dynamics of human immunodeficiency virus type 1 replication in vertically infected infants. J Virol (1999) 1.54
Antibody-dependent cell-mediated cytotoxicity directed by a human monoclonal antibody reactive with gp120 of HIV-1. AIDS (1991) 1.53
Normal immune function and inability to isolate virus in culture in an individual with long-term human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses (1994) 1.51
Primary pulmonary hypertension in patients with classic hemophilia. Ann Intern Med (1988) 1.51
Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. N Engl J Med (1997) 1.50
"Chronic Epstein-Barr virus infection" syndrome and polymyalgia rheumatica. J Rheumatol (1988) 1.50
Serological characterization of HTLV-III infection in AIDS and related disorders. J Infect Dis (1986) 1.47
Inhibition of lymphocyte stimulation by measles virus. J Immunol (1975) 1.47
Supervised patient-management of hemophilia. A study of 45 patients with hemophilia A and B. Ann Intern Med (1973) 1.46
European Epidemiologic Registry of Cystic Fibrosis (ERCF): comparison of major disease manifestations between patients with different classes of mutations. Pediatr Pulmonol (2001) 1.44
Improved lung function tests on changing from topical timolol: non-selective beta-blockade impairs lung function tests in elderly patients. Eye (Lond) (1993) 1.44
Structural displacements in normal swallowing: a videofluoroscopic study. Dysphagia (2000) 1.43
On the antioxidant properties of erythropoietin and its association with the oxidative-nitrosative stress response to hypoxia in humans. Acta Physiol (Oxf) (2014) 1.43
Antioxidants and coronary heart disease. Lancet (1991) 1.43
Activated lymphocytes during acute Epstein-Barr virus infection. J Immunol (1987) 1.42
Transfusion transmission of human T-lymphotropic virus types I and II: lessons to be learned from look-back investigations and implications for patient counseling. Transfusion (1993) 1.42
Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL), virus load, and CD4 T cell loss: evidence supporting a protective role for CTL in vivo. J Infect Dis (1997) 1.41
A clinical comparison of beclomethasone dipropionate delivered by pressurised aerosol and as a powder from a rotahaler. Arch Dis Child (1979) 1.41
Reactive histiocytic disorders. Am J Clin Pathol (1993) 1.41
n-3 fatty acids and cellular aspects of atherosclerosis. Arch Intern Med (1989) 1.39
Vertical transmission of Mycobacterium tuberculosis in KwaZulu Natal: impact of HIV-1 co-infection. Int J Tuberc Lung Dis (2004) 1.39
Racial/ethnic differences in HIV-1 seroprevalence and risky behaviors among intravenous drug users in a multisite study. Am J Epidemiol (1990) 1.38
Differential evolution and stability of epitope-specific CD8(+) T cell responses in EBV infection. J Immunol (2001) 1.37
Cell-mediated immunity to Epstein-Barr-virus-transformed lymphoblastoid cells in acute infectious mononucleosis. N Engl J Med (1975) 1.36
Isolation of human T-cell lymphotropic virus type 2 from Guaymi Indians in Panama. Proc Natl Acad Sci U S A (1990) 1.36
Efficacy of self-therapy in hemophilia. A study of 72 patients with hemophilia A and B. N Engl J Med (1974) 1.36
Destruction of human lymphoid tissue-culture cell lines by human peripheral lymphocytes in 51Cr-release cellular cytotoxicity assays. J Natl Cancer Inst (1974) 1.36